Education
About Us
Working with TipRanks
Follow Us
Zynex (ZYXI)
NASDAQ:ZYXI
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.2Last Year’s EPS
0.04Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: 7.17%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Negative
The earnings call presented a mix of positive developments such as the FDA submission for the NiCO pulse oximeter and cost reduction initiatives, but these were overshadowed by significant revenue decline, increased net loss, and uncertainty regarding the TriCare payment suspension, leading to a challenging financial outlook.Company Guidance
During the Zynex First Quarter 2025 Earnings Conference Call, the company provided guidance amidst challenges with TriCare's temporary payment suspension, impacting their financial results. Revenue for Q1 2025 was reported at $26.6 million, a significant decrease from $46.5 million in the same quarter of 2024, primarily due to TriCare and slowing order growth. The company announced a restructuring plan to operate without TriCare, leading to a 15% staff reduction, expected to save approximately $35 million annually. Despite these setbacks, the company is optimistic about future growth, particularly with the upcoming FDA submission for their NiCO pulse oximeter, which is anticipated to drive revenue in 2026. For Q2 2025, Zynex has projected revenue of $27 million with an EPS loss of $0.20, as they continue to adjust their operations and capitalize on new revenue opportunities.NiCO Pulse Oximeter FDA Submission
Zynex completed and passed all EMC and safety tests for their NiCO pulse oximeter and plans to submit to the FDA shortly. The product is expected to revolutionize the market by providing accurate readings regardless of skin pigmentation, with commercialization anticipated in 2026.
Cost Reduction Measures
Zynex has reduced its corporate staff by 15%, leading to expected annual savings of approximately $35 million. This is part of a broader cost containment strategy to address current challenges.
Diversification of Revenue Streams
The company is targeting new growth areas such as personal injury and increased the proportion of its diversified product orders to 34% in Q1 2025, up from an average of 30% last year.
Strong Cash Position
Zynex maintains a strong balance sheet with $40 million in working capital and approximately $24 million of cash on hand.
ZYXI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ZYXI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | $2.23 | $1.66 | -25.56% |
Mar 11, 2025 | $7.00 | $3.41 | -51.29% |
Oct 24, 2024 | $8.59 | $9.12 | +6.17% |
Jul 25, 2024 | $10.19 | $8.93 | -12.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Zynex (ZYXI) report earnings?
Zynex (ZYXI) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Zynex (ZYXI) earnings time?
Zynex (ZYXI) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZYXI EPS forecast?
ZYXI EPS forecast for the fiscal quarter 2025 (Q2) is -0.2.